The treatment recommendations for chronic myelogenous leukemia (CML) are evolving
rapidly. In the past year, pegylated interferon and STI571 (Gleevec, imatinib mesylate), a Bcr …

Chronic myelogenous leukemia (CML) originates in a pluripotent hematopoetic stem cell of
the bone marrow and is characterized by greatly increased numbers of granulocytes in the …

Chronic myeloid leukemia (CML) is the prototype cytogenetic malignancy. Even before the
development of basic G-and R-banding techniques, CML was found to be associated with a …

Chronic myeloid leukemia (CML) has become a model in research and management among
malignant disorders. Since the discovery of the presence of a unique and constant …

Chronic myeloid leukaemia (CML) can be considered as a paradigm for neoplasias that
evolve through a multi-step process. CML is also one of the best examples of a disease that …

The chronological history of the important discoveries leading to our present understanding
of the essential clinical, biological, biochemical, and molecular features of chronic …

In less than 10 years, the prognosis of chronic myeloid leukaemia has changed from that of
a fatal disease to a disorder amenable simply to lifelong oral medication and compatible …

Chronic myeloid leukemia (CML) has been a “model disease” with a long history. Beginning
with the first discovery of leukemia and the description of the Philadelphia Chromosome and …

With the deaths of Janet Rowley and John Goldman in December 2013, the world lost two
pioneers in the field of chronic myeloid leukemia. In 1973, Janet Rowley, unraveled the …

Chronic myelogenous leukemia is a myeloproliferative disorder. It is characterized by a
biphasic or triphasic clinical course in which a benign chronic phase is followed by …